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Abstract Benign familial neonatal convulsion (BFNC) is
a rare autosomal dominant disorder caused by mutations in
KCNQ2 and KCNQ3, two genes encoding for potassium
channel subunits. A large family with nine members affected
by BFNC is described in the present study. All affected mem-
bers of this family carry a novel deletion/insertion mutation in
the KCNQ2 gene (c.761_770del10insA), which determines a
premature truncation of the protein. In addition, in the family
of the proposita’s father, a novel sequence variant (c.2687A>
G) in KCNQ3 leading to the p.N821S amino acid change was
detected. When heterologously expressed in Chinese hamster
ovary cells, KCNQ2 subunits carrying the mutation failed to
form functional potassium channels in homomeric configu-
ration and did not affect channels formed by KCNQ2 and/or
KCNQ3 subunits. On the other hand, homomeric and het-
eromeric potassium channels formed by KCNQ3 subunits
carrying the p.N821S variant were indistinguishable from
those formed by wild-type KCNQ3 subunits. Finally, the
current density of the cells mimicking the double hetero-
zygotic condition for both KCNQ2 and KCNQ3 alleles of the
proband was decreased by approximately 25% when com-
pared to cells expressing only wild-type alleles. Collectively,
these results suggest that, in the family investigated, the
KCNQ2 mutation is responsible for the BFNC phenotype,
possibly because of haplo-insufficiency, whereas the KCNQ3
variant is functionally silent, a result compatible with its lack
of segregation with the BFNC phenotype.
Keywords Epilepsy . Benign familial neonatal
convulsion . KCNQ2 . KCNQ3 . Gene variant
Introduction
Benign familial neonatal convulsions (BFNC; MIM
121200) is a rare autosomal-dominant idiopathic epilepsy
of the newborn. This disease is characterized by the occur-
rence of multifocal or generalized tonic-clonic convulsions
starting at around day 3 of postnatal life and spontaneously
disappearing after a few weeks or months [1]. Although
neurocognitive development is normal in most BFNC-
affected individuals, 10–15% of them experience convul-
sive manifestations later in life [2].
Mutations in either KCNQ2 [3, 4] or KCNQ3 [5] genes
have been causally linked to BFNC, although about 30% of
BFNC-affected families fail to show KCNQ2 or KCNQ3
mutations or linkage to KCNQ2 or KCNQ3 loci [6].
KCNQ2 and KCNQ3 genes encode for voltage-gated K+
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channel subunits whose heteromeric assembly underlies
the muscarinic-regulated K+ current (IKM) [7]. IKM is a
widespread regulator of neuronal excitability limiting re-
petitive firing and causing spike-frequency adaptation [8].
Around 30 KCNQ2 and 3 KCNQ3 mutations have been
discovered so far in families affected by BFNC [6]. Those
few mutations whose functional consequences have been
investigated cause a variable reduction (usually less than
50%) in the maximal current carried by heteromeric
KCNQ2/KCNQ3 channels [9–11]; a current reduction of
more than 50% was found only in two cases, consistent
with a dominant-negative effect [6, 12].
In the present study, we report clinical and genetic data
on a large Italian BFNC family with nine affected members.
In the index patient, we found heterozygous sequence var-
iants in both KCNQ2 and KCNQ3 alleles; a c.761_770del
10insA in KCNQ2, determining a premature truncation of
the protein, and a c.2687A>G substitution in KCNQ3,
leading to the p.N821S amino acid change. In transfected
mammalian cells, functional analysis by biochemical and
electrophysiological means revealed that the KCNQ2muta-
tion failed to give rise to significant voltage-gated K+ cur-
rents and did not affect channels formed by KCNQ2 and/or
KCNQ3 subunits; on the other hand, KCNQ3 subunits
carrying the c.2687A>G substitution displayed functional
properties indistinguishable from those formed by wild-
type KCNQ3 subunits.
Patients and methods
Clinical data
The pedigree of the family investigated is shown in Fig. 1a.
Subject IV-1(proband)
The index patient (Case IV-1, Fig. 1a) was the only
daughter of two unrelated parents, delivered after a trouble-
free pregnancy. At the age of 3 days, she had sub-con-
tinuous clonic seizures involving bilaterally upper and
lower extremities with perioral cyanosis, lasting for 50–
60 mins, and stopped by phenobarbital (PB; 20 mg kg-1) i.
v. in bolo. Despite immediately starting PB treatment
(4.2 mg kg-1 day-1) as chronic therapy, isolated, rare (two to
three per day) and brief (5–10 s) seizures appeared during
the next 3 days. At the age of 7 days, during a video-EEG
recording, she suffered from a more prolonged clonic seizure
(lasting 1 min), showing right head and eyes rotation,
palpebral myoclonias and oro-alimentary automatisms. Cy-
anosis was evident. The EEG showed fast polispikes on the
left centro-temporal areas; a secondary diffusion of spikes
and spikes and waves complexes was evident on the left
hemisphere and the centro-temporal right areas. Interictal
EEG recording showed a normal organization of background
activity with centro-temporal isolated spikes more evident on
the left side. Neurological assessment between seizures and
laboratory data (complete blood count, electrolytes, blood
urea nitrogen, blood gas analysis, blood glucose) were nor-
mal. Cerebral ecography and cerebral MRI were normal.
Starting from the age of 6 months, the EEG has been normal.
After two isolated brief convulsive episodes occurring at the
13th and 15th day, no more seizures were noticed; PB was
discontinued at the age of 12 months. She is now 18 months
old; her neurological examination and psychomotor devel-
opment are normal.
Subjects in the maternal lineage
At the age of 3 days, the mother of the proband (case III-5)
had the same type of seizures described in her daughter
(with the exception of the duration, which was shorter), but
these seizures spontaneously remitted after 1–2 min. Seizures
(one to two per week) continued for months and disappeared
before the sixth month of life without any pharmacological
treatment. Analogously, many subjects in the maternal line-
age (subjects II-4, II-5, II-6, III-7) showed seizures starting at
the age of 3–5 days and disappearing after 5 months without
any anti-epileptic drug (AED) therapy. On the contrary,
although subjects III-10 and III-11 had seizures at the same
age, they immediately underwent PB treatment, and seizures
disappeared in 1 week. At the time of writing, they showed
no neurological abnormalities and normal IQ.
Subject III-4, the maternal aunt of the proband, was born
after a trouble-free pregnancy at 40 weeks. Birth clinical
documents do not report relevant perinatal events. Starting
from the age of 3 days, she had rare and brief clonic
seizures (one or two per week). No therapy was introduced.
At the age of 6 months, she had a prolonged tonic seizure
with cyanosis, for which hospitalization in intensive care
unit was necessary. EEG recording showed multifocal
epileptiform abnormalities asynchronous over both cere-
bral hemispheres. Screening laboratory data (complete
blood count, electrolytes, blood urea nitrogen, blood gas
analysis, blood glucose, cerebrospinal fluid cytology) and
CT scan were normal. Despite PB treatment, she continued
to have seizures; ACTH treatment was started, and com-
plete seizures control was immediately achieved. No more
seizures were noticed after this time; PB was discontinued
at the age of 36 months. A mild developmental delay in the
first years of life and mild learning disabilities during
school age were observed. She is now 37 years old, without
major neurological deficit but with mild mental retardation
(full IQ=65, by WAIS-R).
Neurological history was unremarkable for individuals
II-3, II-7, III-6, III-8 and III-9.
Subjects in the paternal lineage
The father of the proposita (case III-1) was born at term by
a spontaneous vaginal delivery following an uncompli-
cated gestation. He had a normal neurological and psy-
chological development and normal schooling. Seizures
have never been described in his life. At the age of 10, he
suffered from migraine with typical aura. Crises were
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frequent in adolescence, but are now less numerous (one or
two episodes per year). Symptoms started with right arm
paraesthesiae, followed by aphasia and visual negative
scotomas. Neurological exam, EEG and MRI are normal.
At the age of 20 months, his sister (case III-3) presented a
single febrile tonic-clonic convulsion lasting 3–5 min. No
therapy was started, and no seizures relapsed during the
following years. At the age of 11, she suffered from mi-
graine with typical aura, with the same characteristics
described for the brother’s attacks. She is now a 30-year-
old woman without any neurological problem. Neurologi-
cal history was unremarkable for individuals II-2 and III-2.
KCNQ2/KCNQ3 genes mutation analysis
Blood samples were taken with informed consent from all
available affected and non-affected members of the family.
Total DNA was extracted from 5 ml of blood with the
IsoQuick Nucleic Acid Extraction kit (ORCA Research,
Bothell, WA, USA). KCNQ2 and KCNQ3 genomic se-
quences were available at the Human Genome Browser
Gateway (http://genome.ucsc.edu/cgi-bin/hgGateway). All
nucleotide numbers refer to the published cDNA sequences:
NM_004518 (KCNQ2) and NM_004519 (KCNQ3). All
exons of KCNQ2 and KCNQ3 were amplified with 17 and
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Fig. 1 Pedigree and genomic
DNA analysis of the BFNC-
affected family. a Pedigree of
the family; solid black symbols
are BFNC-affected subjects,
while open symbols represent
healthy individuals; horizontal
hatched circle represents a sub-
ject with BFNC who later de-
veloped West syndrome; the
arrow indicates the proband; NA
blood sample not available.
Empty dots mark subjects of the
family carrying the KCNQ2
mutation, while stars indicate
those carrying KCNQ3 gene
variant. b Electropherograms of
genomic DNA fragments con-
taining the sequence variants
identified in KCNQ2 (left pan-
els) and KCNQ3 (right panels).
In the top left panel, the arrow
indicates the site of insertion/
deletion. The boxed sequence in
the control (middle left panel)
represents the deleted sequence.
In the bottom left panel, the
sequence of the isolated and
subcloned mutated allele is
shown; the boxed nucleotide
shows the inserted adenine nu-
cleotide at the insertion/deletion
site. In the top right panel, the
arrow indicates the nucleotide
change detected in the proband
(top, IV-1) and in the father
(bottom, III-1), while the mother
(middle, III-V) shows a wild-
type sequence
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15 sets of primers, respectively. Amplification was per-
formed in a Master cycler Gradient (Eppendorf, Hamburg,
Germany) using 25 pmol of each primer and 0.5 U Taq
Gold DNA polymerase (Applied Biosystems, Foster City,
CA, USA) in 35 cycles according to the manufacturer’s
instructions. Mutation analysis was performed by direct
sequencing of all exons with the same primers used for
amplification (primer sequences are available on request).
PCR products were treated with ExoSAP-IT (USB Cor-
poration, Cleveland, OH, USA) and then directly se-
quenced with Big Dye Terminator Cycle Sequencing Kit in
an automated sequencer (ABI 3100 PE, Applied Biosys-
tems). Control subjects were recruited from the same
Italian regions where the family comes from and were
checked by direct sequencing for the presence of the nu-
cleotide variations under examination. All mutations are
described according to the mutation nomenclature ([13]
and at the http://www.hgvs.org/mutnomen). The ins/del
mutation in KCNQ2 gene was first characterized by sub-
cloning and sequencing of two independent PCR products.
In addition to that, since this mutation produces the loss of
an HpaII restriction enzyme site, the segregation of this
mutation in the family was verified both by restriction
enzyme analysis and by sequencing. NetStart program
(version1.0) is available at http://www.cbs.dtu.dk/services/
NetStart/.
Mutagenesis of KCNQ2 and KCNQ3
Mutations were engineered on human KCNQ2 and KCNQ3
cDNAs cloned into pcDNA3.1 (Invitrogen, Milan, Italy) by
sequence overlap extension PCR with the Pfu DNA
polymerase, as described in [14]. For some experiments,
the KCNQ2mutation was incorporated in a cDNA construct
encoding for a fusion protein (EGFP-Q2) between KCNQ2
and the Enhanced Green Fluorescent Protein (EGFP), in
which the EGFP was covalently linked at the N terminus of
the KCNQ2 subunit by means of a 7 glutamine (Q) residues
spacer to increase protein flexibility at the junction site
(Soldovieri et al., manuscript in preparation).
Heterologous expression of wild-type and mutant
KCNQ subunits
Channel subunits were expressed in Chinese hamster
ovary (CHO) cells by transient transfection. CHO cells
were grown in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% foetal bovine serum (FBS),
non-essential amino acids (0.1 mM), penicillin (50 U ml-1)
and streptomycin (50 μg ml-1) in a humidified atmosphere
at 37°C with 5% CO2 in 100-mm plastic Petri dishes. For
electrophysiological experiments, the cells were seeded on
glass coverslips (Carolina Biological Supply Company,
Burlington, NC, USA) and transfected on the next day with
the appropriate cDNAs using Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s protocol, always
using a total amount of 4 μg of cDNA. When needed, a
plasmid encoding for enhanced green fluorescent protein
(EGFP) (Clontech, Palo Alto, CA, USA) was used as
transfection marker. All the experiments were performed
1–2 days after transfection.
Electrophysiology
Currents fromCHO cells were recorded at room temperature
(20–22°C) using a commercially available amplifier (Ax-
opatch 200A, Axon Instruments, Foster City, CA, USA) and
the whole-cell configuration of the patch-clamp technique,
using glass micropipettes of 3–5 MΩ resistance. The
extracellular solution contained (in millimolar): 138 NaCl,
2 CaCl2, 5.4 KCl, 1 MgCl2, 10 glucose and 10 HEPES, pH
7.4 with NaOH; the pipette (intracellular) solution contained
(in millimolar): 140 KCl, 2 MgCl2, 10 EGTA, 10 HEPES,
5 Mg-ATP, 0.25 cAMP, pH 7.3–7.4 with KOH. The
pCLAMP (version 6.0.4, Axon Instruments) software was
used for data acquisition and analysis. Data are expressed as
the mean±SEM.When necessary, statistical differences were
evaluated with the Student’s t test (p<0.05).
Western blots
Twenty-four hours post-transfection, CHO cells were lysed,
and KCNQ2 subunit expression was investigated by West-
ern blotting on 6% SDS-PAGE gels using three different
antibodies: one against an epitope in the KCNQ2N-terminal
region (sc-7793; Santa Cruz, CA, USA; 1:200 dilution),
another against a C-terminal epitope in KCNQ2 (sc-7792;
Santa Cruz, CA, USA; 1:200 dilution) and a third one
against an epitope in the EGFP sequence (Clontech; 1:1,000
dilution), followed by chemiluminescence detection. The
same blots were stripped and reprobed with an anti-α-
tubulin antibody (Sigma, Milan, Italy; dilution 1:2,000) to
check for equal protein loading. Images were captured and
stored on a ChemiDoc station and analysed with the
Quantity One analysis software (BioRad, Segrate, Italy).
Statistical analysis
Statistical comparisons between experimental groups were
performed using the Student’s t test. Differences were
considered to be statistically significant when p values
were less than 0.05.
Results
Molecular genetic analysis
Mutation analysis of the KCNQ2 and KCNQ3 genes was
performed on the DNA of the index case of the family. The
entire coding regions and the exon–intron junctions of
KCNQ2 and KCNQ3 were analysed by direct sequencing.
In this subject, KCNQ2 showed a heterozygous deletion of
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10 bp and an insertion of a single adenine nucleotide in
position 761 of the cDNA sequence (c.761_770del10insA)
(Fig. 1b). This mutation generated a stop codon at the
deletion/insertion site, thus producing a truncated N-ter-
minal peptide of 194 residues. Twenty-seven base pairs
downstream the stop codon, a second open reading frame is
maintained, starting at the ATG corresponding to the me-
thionine in position 208 of the wild-type KCNQ2 sequence.
Bioinformatic analysis using the NetStart program (version
1.0) indicates a low score, 0.383, for this ATG, 0.5 being the
minimal value required for an ATG to represent a probable
translation start site. The presence of the mutation generates
a loss of one HpaII restriction enzyme site, which was used
to follow the segregation of the mutation in the family
together with the direct sequencing of the PCR product.
Thus, the c.761_770del10insA mutation was found in the
proband (IV-1), in her mother (III-5), in two affected
maternal aunts (III-4 and III-7) and in the maternal grand-
mother (II-5). The grandmother’s sister (II-6) and two of her
four children (III-10 and III-11) are also carrying the same
mutation.
Subsequent analysis of the coding region of KCNQ3 in
the proband led to the identification of a heterozygous base
change (c.2687A>G), leading to the p.N821S amino acid
substitution. This KCNQ3 gene variant is inherited from
the father (III-1) and is also present in his brother and sister
(III-2 and III-3) and in the paternal grandfather (II-1), while
it was not detected in 300 control chromosomes from
healthy individuals. Thus, the proband is a double hetero-
zygous for the insertion/deletion in KCNQ2 inherited from
the mother and the single base substitution in KCNQ3
inherited from the father.
Biochemical analysis of wild-type and mutant
KCNQ2 subunits heterologously expressed
in CHO cells
Since the KCNQ2 mutation generated a stop codon at
position 194 followed by an inframe ATG, the possibility
existed that the KCNQ2 mutant allele generated in vivo
two putative peptides corresponding to partial KCNQ2 se-
quences: the first corresponding to the N-terminal 194
amino acids and the second containing the last 665 amino
acids of the C-terminus.
To investigate the biochemical consequences of this
mutation and particularly whether the downstream C-
terminal fragment was being synthesized in vivo, we per-
formed Western blot experiments in CHO cells transfected
with plasmids encoding for wild-type or mutant KCNQ2
subunits using three different antibodies. The first antibody
recognized an epitope natively present in the N-terminus of
KCNQ2 (anti-Q2N Ab). Using this antibody, wild-type
KCNQ2 subunit expression was revealed by a single
immunoreactive band of an approximate molecular weight
(MW) of 95 kDa, as previously shownwith other antibodies
[15] (Fig. 2a, lane 2). By contrast, in cells transfected with
the plasmid encoding for KCNQ2 subunits carrying the
c.761_770del10insA mutation, a single immunoreactive
band of an approximate MW of 21 kDa was revealed
(Fig. 2a, lane 3), which closely matched that expected for
the N-terminal fragment of 194 residues. Interestingly, in
cells transfected with the cDNA encoding for wild-type
EGFP-KCNQ2 fusion proteins, this antibody revealed a
single band of a MWof approximately 130 kDa, consistent
with the MW of the EGFP-KCNQ2 fusion subunit. By
contrast, in lysates from cells transfected with the EGFP-
KCNQ2 plasmid carrying the c.761_770del10insA muta-
tion, the antibody revealed a predominant band of about
55 kDa in size, presumably corresponding to the EGFP
covalently linked to the 194 amino acid N-terminal frag-
ment generated by the mutation found in our family. Similar
results were also observed when a monoclonal antibody
directed against EGFP was used (Fig. 2b). This antibody
failed to recognize any band in cells transfected with non-
EGFP fusion constructs (lanes 2 and 3), whereas it recog-
nized a single band of approximately 130 kDa in wild-type
EGFP-KCNQ2-transfected cells (lane 4) and a prominent
band of about 55 kDa in size in cells transfected with the
EGFP-KCNQ2 plasmid carrying the c.761_770del10insA
mutation (lane 5).
Interestingly, no band was observed in cells transfected
with plasmids encoding for the c.761_770del10insA mu-
tation, either in the non-fusion protein (Fig. 2c; lane 3) or in
EGFP-KCNQ2 fusion constructs (Fig. 2c; lane 5), when an
antibody recognizing an epitope natively present in the C-
terminus of KCNQ2 (anti-Q2C Ab) was used; by contrast,
the usual 95 or 130 kDa bands were clearly detected in
KCNQ2- (Fig. 2c; lane 2) or EGFP-KCNQ2-transfected
cells (Fig. 2c; lane 4), respectively.
Electrophysiological properties of wild-type
and mutant subunits
Heterologous expression of wild-type KCNQ2 subunits
led to the appearance of voltage-dependent K+-selective
currents characterized by a rather slow time-course of
activation and deactivation and a threshold for current ac-
tivation of around −50 mV (Figs. 3a and b). Interestingly,
macroscopic K+ currents formed by EGFP-KCNQ2 sub-
units were indistinguishable in size and functional proper-
ties from those formed by non-fusion KCNQ2 subunits. In
fact, the density of the macroscopic K+ currents recorded at
+20 mV in EGFP-KCNQ2-transfected cells was 36.4±
6.3 pA/pF (n=30), whereas that of KCNQ2-transfected
cells was 51.5±7.1 pA/pF (n=38; p>0.05). In addition, the
gating properties of homomeric channels formed by
KCNQ2 or EGFP-KCNQ2 subunits were indistinguish-
able (Soldovieri et al., manuscript in preparation).
By contrast, the density of the macroscopic K+ currents
recorded at +20 mV in cells transfected with the plasmids
encoding for KCNQ2 subunits carrying the c.761_770del
10insA mutation (1.1±0.2 pA/pF; n=11) was indistinguish-
able from that found in cells transfected with EGFP alone
(0.6±0.1 pA/pF; n=7) (Fig. 2b), suggesting that mutant
subunits failed to give rise to measurable currents. Similar
results were also observed in cells expressing EGFP-
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KCNQ2 c.761_770del10insA mutant subunits (the K+
current density at +20 mV in these cells was 0.7±0.2 pA/
pF; n=6). Interestingly, transfection with plasmids encod-
ing for c.761_770del10insA mutant KCNQ2 subunits did
not affect the current density recorded from wild-type
KCNQ2-transfected cells (Fig. 3b).
In CHO cells, expression of KCNQ3 subunits in
homomeric configuration generates functional voltage-
dependent K+ currents, although the current density re-
corded from KCNQ3-transfected cells is lower than that
measured in cells expressing KCNQ2 subunits homomeri-
cally (Figs. 3a and b). K+ current density generated upon
CHO cells transfection with KCNQ3 p.N821S subunits
was identical to that found in KCNQ3-transfected cells
(Figs. 3a and b). Interestingly, the kinetics and the voltage-
dependence of these mutant KCNQ3 currents also were
indistinguishable from those carried by homomeric wild-
type KCNQ3 channels (data not shown). Furthermore,
mutant KCNQ2 subunits failed to affect homomeric
channels composed of wild-type or mutant KCNQ3 sub-
units (Fig. 3b).
Heteromeric assembly KCNQ2 and KCNQ3 subunits
seems to represent the main molecular substrate of the M-
current [7]. Co-expression of KCNQ3 with KCNQ2
subunits generates macroscopic currents much larger than
those expected from simple summation of homomeric
KCNQ3 or KCNQ2 currents (Fig. 3c). K+ current densities
recorded in KCNQ3 p.N821S plus KCNQ2 transfected
cells were similar to those observed upon KCNQ3 plus
KCNQ2 subunits co-expression (Fig. 3c), suggesting that
mutant KCNQ3 subunits were fully able to substitute for
wild-type KCNQ3 subunits in forming heteromeric chan-
nels with KCNQ2 subunits. To verify this hypothesis, we
compared the TEA sensitivity of the currents recorded from
cells co-expressing KCNQ3 p.N821S and KCNQ2 sub-
units with that of cells co-expressing wild-type KCNQ3
and KCNQ2 subunits, taking advantage of the tenfold
lower sensitivity to pharmacological blockade by TEA of
heteromeric channels when compared to homomeric
KCNQ2 channels. As shown in Fig. 3d, the percentage
of current blockade by 0.3 and 3 mM TEA was identical
between cells expressing KCNQ2 plus KCNQ3 and
KCNQ2 plus KCNQ3 p.N821S subunits, confirming the
ability of mutant KCNQ3 subunits to form heteromultimers
with wild-type KCNQ2 subunits. Furthermore, expression
of KCNQ2 subunits carrying the c.761_770del10insA
mutation failed to modify TEA sensitivity of homomeric
channels composed of wild-type KCNQ2 subunits
(Fig. 3d).
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Fig. 2 Biochemical analysis of wild-type and mutant KCNQ2
subunits heterologously expressed in CHO cells. Western blot
analysis on total cell lysates from control CHO cells (lanes 1) or
from cells transfected with the plasmids encoding for KCNQ2 (lanes
2), KCNQ2 c.761_770del10insA (lanes 3), EGFP-KCNQ2 (lanes 4)
or EGFP-KCNQ2 c.761_770del10insA (lanes 5). Protein expression
in the blots of the upper part of the figure was revealed by the
following primary antibodies: a a polyclonal antibody recognizing
an epitope natively present in the N-terminus of KCNQ2 (anti-Q2N
Ab), b a monoclonal antibody directed against EGFP (anti-EGFP)
and c a polyclonal antibody recognizing an epitope natively present
in the C-terminus of KCNQ2 (anti-Q2C Ab). The lower blots in
each panel show the expression, on the same filters, of α-tubulin,
used as an internal standard for equal protein loading. In the upper
blots of each panel, the arrows on the right indicate the MW of the
major bands revealed: the band of an approximate MW of 130 kDa
corresponds to full-length EGFP-KCNQ2 subunits, the band of an
approximate MW of 95 kDa corresponds to full-length KCNQ2
subunits, the band of approximate MW of 55 kDa corresponds to
EGFP-KCNQ2 subunits truncated by the c.761_770del10insA
mutation, the band of an approximate MW of 21 kDa corresponds
to KCNQ2 subunits truncated by the c.761_770del10insA mutation.
On the left of each panel, the positions and MW of known proteins
used as standards is shown. In lanes 4 and 5 of both panels a and b,
other bands in the 30–40 kDa MW range were evident; these bands
are likely to represent various forms of EGFP or EGFP-KCNQ2
fusion proteins. An additional band of approximately 80 kDa in
lanes 2 and 4 of panel c was consistently observed; the nature of this
band is unknown at the moment
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Finally, the simultaneous expression of all four cDNAs
encoding for each subunit type (Q2, Q2V, Q3 and Q3V) in a
0.5:0.5:0.5:0.5 ratio caused a decrease in the K+ current
density of approximately 25% when compared to that re-
corded in cells expressing wild-type KCNQ2 and KCNQ3
subunits in a 1:1 ratio (Fig. 3c).
Discussion
Clinical and genetic data from a large BFNC family with
nine affected members are reported in the present study.
Eight of the affected members exhibit typical BFNC, with
seizure occurrence on day 3 and remission before 4–5
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Fig. 3 Electrophysiological properties of wild-type and variant
KCNQ2 and KCNQ3 subunits heterologously expressed in CHO
cells. a Representative patch-clamp recordings from CHO cells
transfected with the plasmids encoding for KCNQ2 (Q2), KCNQ2
c.761_770del10insA (Q2V), KCNQ3 (Q3) or KCNQ3 p.N821S
(Q3V), as indicated. Holding potential: −80 mV; step potentials from
−80 to +20 mV, in 20-mV steps, followed by a pulse to a constant
value of 0 mV of 375–600 ms. b, c Quantification of the current
densities recorded from the experimental groups indicated at the
bottom of the panels. Current densities were calculated by dividing
the peak current at the end of the +20-mV pulse by the membrane
capacitance in each recorded cell. Each bar is the mean±SEM of 11–
32 cells recorded from at least two different transfections. In panel b,
* indicates values statistically different from control (C) values but
not between each other; ** indicates values statistically different
from control (C) and from Q2 and Q2+Q2V values, but not among
each other. In panel c, * indicates values statistically different from
Q2 and Q3 values, but not between each other; ** indicates a value
that is statistically different from control (C) and from Q2 and Q3
values, as well as from that of the Q2+Q3 group. d Time-course of
the effects of the indicated concentrations of TEA on the currents
recorded from cells transfected with the plasmids encoding for
KCNQ2 (filled circles), KCNQ2 plus KCNQ2 c.761_770del10insA
(empty circles), KCNQ2 plus KCNQ3 (filled squares) and KCNQ2
plus KCNQ3 p.N821S (empty squares). K+ currents in these cells
were activated with voltage pulses at 0 mV, each lasting 2 s,
delivered at a frequency of 0.1 Hz; solution changes were performed
via a computer-controlled fast-perfusion apparatus. For each cell, the
currents measured at the end of the 0-mV pulse were normalized to
the maximal value; the results from four cells per experimental
group were averaged and expressed as a function of time. The boxes
on top of the panel correspond to the duration of the TEA exposures
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months of age. During this period of time, seizure fre-
quency was quite variable among different members of the
family. Nevertheless, direct comparison among these
individuals cannot be made because in some cases, PB
therapy was started early (at the time the first seizure oc-
curred, as in subjects III-10 and III-11), while in others, no
AED therapy was administered (subjects IV-1, III-7, II-4,
II-5, II-6).
In one BFNC-affected member of the family (individual
III-4), who did not undergo early AED treatment, a severe
type of epilepsy (West Syndrome) occurred at 6 months of
age, and a mild mental retardation and neurological prob-
lems relapsed in adult life, consistent with the fact that 10–
15% of BFNC individuals experience convulsive manifes-
tations later in life [2]. At this stage, it is hard to establish
whether the different outcome of these patients is due to a
partly different genetic background or whether it is a
consequence of the severe type of epilepsy that occurred
early in life.
As a matter of fact, all family members suffering from
BFNC carry an identical novel deletion/insertion mutation
in the KCNQ2 gene (c.761_770del10insA). This is in
agreement with what has already been reported in the
literature [6, 16, 17], where several pedigrees show a wide
range of severity in the clinical phenotype apparently
associated to the same KCNQ2 mutation without excluding
the possible involvement of other environmental or genetic
factors.
KCNQ2 subunits display a putative secondary structure
with six transmembrane domains (from S1 to S6); therefore,
this mutation led to KCNQ2 truncation at position 194,
immediately before the S4 domain, the main structural
element for voltage sensing [18]. When heterologously
expressed in mammalian cells by transient transfection
procedures, KCNQ2 subunits carrying the c.761_770del
10insA mutation were synthesized in significant amount,
as revealed by the ability of antibodies directed against
native or artificially engineered N-terminal epitopes to de-
tect truncated fragments of the KCNQ2 subunit of ap-
propriate molecular sizes in Western blot experiments.
However, electrophysiological experiments carried out in
the same cells revealed that mutant KCNQ2 subunits were
unable to form functional homomeric K+ channels. This
result is consistent with the notion that the mutation
generated truncated KCNQ2 subunits lacking most of the
voltage-dependent gating determinants (the S4 segment in
particular), as well as the S5–S6 region, where the molec-
ular determinants for K+ selectivity are located [19]. We
also checked the possibility that, in addition to the 194-
amino-acid N-terminal fragment, the KCNQ2 mutant allele
might have generated a 665-amino-acid C-terminal frag-
ment encompassing a large part of the KCNQ2 subunit,
including the critical regions needed for regulation by
protein kinase C, A-kinase anchoring proteins [20] and
calmodulin [21, 22]. In fact, in other ion channels including
K+ channels, it has been reported that splitting the subunits
and expressing the two domains separately or in isolation
may generate ion channels with novel functional properties
[23]. However, Western blot experiments performed using
antibodies targeting an epitope in the C-terminal region of
KCNQ2 subunits failed to detect significant amounts of C-
terminal fragments in cells transfected with the mutant
KCNQ2, arguing against the possibility that this C-ter-
minal fragment might have been responsible for the
mutation-induced suppression of the K+ channel function
revealed by the present electrophysiological experiments.
Furthermore, mutant KCNQ2 subunits did not exert
dominant-negative effects since they failed to interfere
with the ability of wild-type KCNQ2 or KCNQ3 subunits
to form functional channels; as a matter of fact, truncated
subunits generated by the mutation lacked the C-terminal
subunit interaction domain (or sid) required for homomeric
and heteromeric subunit assembly [24, 25]. This result also
supports the notion that the KCNQ2 C-terminal fragment
encompassing the sid domain, which might have prompted
dominant-negative effects, was not synthesized upon
transfection with KCNQ2 c.761_770del10insA subunits.
Interestingly, in addition to the described KCNQ2 mu-
tation, in the family of the proposita’s father, the p.N821S
amino acid substitution was detected. N821 is not par-
ticularly conserved among the other members of the
KCNQ potassium channel family, and the substituting
serine residue is present in the rat, mouse and bos taurus
orthologs of KCNQ3. When heterologously expressed in
CHO cells, homomeric potassium channels formed by
KCNQ3 subunits carrying the p.N821S replacement were
indistinguishable from those formed by wild-type KCNQ3
subunits. Furthermore, the p.N821S variant did not in-
terfere with the ability of KCNQ3 subunits to form het-
eromeric channels with KCNQ2 subunits. These results
suggested that the p.N821S amino acid change in KCNQ3
was not responsible for BFNC in the family here in-
vestigated. Indeed the KCNQ3 c.2687A>G substitution did
not segregate with the BFNC phenotype. Furthermore, the
observation that the c.2687A>G nucleotide change was not
found in 300 alleles from control healthy individuals
suggests that this gene variant is likely to represent a rare
KCNQ3 gene polymorphism. Indeed the presence of
KCNQ3 variant was observed in four subjects within the
paternal lineage, two of them showing migraine with
typical aura and one of them associated also to one event of
febrile convulsion. In spite of the fact that functional data
obtained do not support a clear role for KCNQ3 variant in
the migraine phenotype here observed, we cannot exclude
that this variant, maybe in association with some other
genetic factor, could have some role in the pathogenesis of
these paroxysms.
Finally, we attempted to mimic the double heterozygous
condition of the proband by simultaneously co-expressing
in our heterologous system all four cDNAs reproducing
each of the two alleles present at the KCNQ2 and KCNQ3
loci of the proband at a 0.5:0.5:0.5:0.5 ratio. The fact that
the K+ current density in these cells was reduced by
approximately 25% when compared to cells expressing
only the two wild-type KCNQ2 and KNCQ3 subunits at a
1:1 ratio argues against possible dominant-negative effects
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caused by variant alleles and is in line with the hypothesis
that a rather small IKM deficit is sufficient to cause BFNC
[3–5].
Collectively, the present results suggest that, in the
family investigated, the KCNQ2 mutation segregates with
the BFNC phenotype and is likely to be responsible for the
BFNC phenotype. Haplo-insufficiency caused by the mu-
tant KCNQ2 allele, rather than dominant-negative effects,
seems to represent the primary mechanism for IKM deficit
and BFNC pathogenesis in the affected family. On the other
hand, the KCNQ3 gene variant is functionally silent, a
result compatible with its lack of segregation with BFNC.
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